Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib versus imatinib plus hydroxychloroquine in chronic myeloid leukaemia with residual molecular disease
ISRCTN61568166Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Apr 2010
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial in chronic myelogenous leukemia (CML) comparing Imatinib alone with Imatinib + hydroxychloroquine (2 arms). Primary endpoint: Treatment success at 12 months. Started Apr 2010; status: completed.
02
Drugs
imatinibhydroxychloroquine
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ISRCTN61568166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN61568166.